These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2017-002530-23 A Randomized, Double blind, Placebo controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Studio clinico randomizzato, in ... 2020-05-06 due-trials
Exempt, with results 2018-002239-11 Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of... 2019-10-24 not-yet-due
Other 2018-004039-64 A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE) not-yet-due
Other 2019-003626-24 An Open-Label, Exploratory Study of the Safety and Preliminary Efficacy of Danicamtiv in Stable Ambulatory Participants with Primary Dilated Cardiomyopathy Due to Either MYH7 or TTN Variants or Other ... not-yet-due
Listed as ongoing, but also has a completion date 2021-005329-26 A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy 2023-03-20 bad-data
Ongoing 2022-001292-14 A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants with Symptomatic Hypertrophic Cardiomyopathy and Left ... not-yet-due

Related organisations

Over time organisations can merge, or split.

We think MyoKardia, Inc. is now effectively part of Bristol-Myers Squibb.